Table 4. The table shows simulated outcomes for 1000 P. vivax malaria patients of undetermined G6PD status at attendance, if they were managed according to each of three strategies (chloroquine, primaquine and screening) according to G6PD status, treatment given and the test result if screened.
| Initial treatment by G6PD status | Males | Females | ||||
|---|---|---|---|---|---|---|
| Strategy | Strategy | |||||
| Chloroquine | Primaquine | Screening | Chloroquine | Primaquine | Screening | |
| G6PD normal who get primaquine and have no recurrences | — | 725 | 718 | — | 592 | 592 |
| G6PD normal who get primaquine and have at least one recurrence | — | 138 | 137 | — | 113 | 113 |
| G6PD normal who get chloroquine only and have no recurrences | 231 | — | 2 | 212 | — | — |
| G6PD normal who get chloroquine only and have at least one recurrence | 632 | — | 6 | 580 | — | — |
| G6PD deficients* who get chloroquine only | 137 | — | — | 208 | — | — |
| G6PD deficients* who get weekly primaquine | — | — | 136 | — | — | 106 |
| Severe G6PD deficients who get 14 day primaquine, do not complete treatment but do not require a transfusion | — | 122 | 1 | — | 40 | 0.40 |
| Intermediate G6PD deficients who get 14 day primaquine and complete treatment | — | — | — | — | 140 | 78 |
| G6PD deficients* who get primaquine, hemolyze and receive a required transfusion | — | 13 | 0.13 | — | 5 | 0.40 |
| G6PD deficients* who get primaquine, hemolyze, do not receive a required transfusion and live | — | 1 | 0.01 | — | 0.50 | 0.04 |
| G6PD deficients* who get primaquine, hemolyze and die due to not receiving a transfusion | — | 0.15 | 0.001 | — | 0.06 | 0.004 |
| Do not receive primaquine due to pregnancy | — | — | — | — | 110 | 110 |
* For women, this includes both severe and intermediate G6PD deficiency.